For pediatric patients with solid tumors, the use of growth factors following chemotherapy evolved from daily filgrastim to pegylated filgrastim. Currently, post‐chemotherapy laboratory work is obtained to monitor for transfusion… Click to show full abstract
For pediatric patients with solid tumors, the use of growth factors following chemotherapy evolved from daily filgrastim to pegylated filgrastim. Currently, post‐chemotherapy laboratory work is obtained to monitor for transfusion needs rather than count recovery. We implemented a clinical practice improvement project aimed at identifying the minimum number of labs required to assess transfusion needs, based upon disease and chemotherapeutic regimen, to design guidelines to safely reduce the number of home labs for targeted solid tumor diagnoses by 50% over 2 years.
Journal Title: Cancer Medicine
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!